{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Castration-resistant+Prostate+Cancer+%28mCRPC%29&page=2",
    "query": {
      "condition": "Metastatic Castration-resistant Prostate Cancer (mCRPC)",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Castration-resistant+Prostate+Cancer+%28mCRPC%29&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-21T23:28:42.636Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04506567",
      "title": "Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Fractionated dose of 225Ac-J591",
          "type": "DRUG"
        },
        {
          "name": "68Ga-PSMA-HBED-CC injection",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Multiple single doses of 225Ac-J591",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "MALE",
        "summary": "18 Years to 99 Years · Male only"
      },
      "enrollment_count": 60,
      "start_date": "2020-08-18",
      "completion_date": "2026-06",
      "has_results": false,
      "last_update_posted_date": "2026-02-17",
      "last_synced_at": "2026-05-21T23:28:42.636Z",
      "location_count": 2,
      "location_summary": "Brooklyn, New York • New York, New York",
      "locations": [
        {
          "city": "Brooklyn",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04506567"
    },
    {
      "nct_id": "NCT04631744",
      "title": "Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Cabozantinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "MALE",
        "summary": "18 Years to 99 Years · Male only"
      },
      "enrollment_count": 4,
      "start_date": "2021-03-03",
      "completion_date": "2025-11-09",
      "has_results": true,
      "last_update_posted_date": "2026-05-01",
      "last_synced_at": "2026-05-21T23:28:42.636Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04631744"
    },
    {
      "nct_id": "NCT05075577",
      "title": "EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with MCRPC",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "EPI-7386 with Enzalutamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ESSA Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 77,
      "start_date": "2021-12-21",
      "completion_date": "2025-01-14",
      "has_results": false,
      "last_update_posted_date": "2025-02-28",
      "last_synced_at": "2026-05-21T23:28:42.636Z",
      "location_count": 13,
      "location_summary": "Tucson, Arizona • Port Saint Lucie, Florida • Tampa, Florida + 8 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Port Saint Lucie",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05075577"
    },
    {
      "nct_id": "NCT03454451",
      "title": "CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer",
        "Renal Cell Cancer",
        "Colorectal Cancer",
        "Triple Negative Breast Cancer",
        "Cervical Cancer",
        "Ovarian Cancer",
        "Pancreatic Cancer",
        "Endometrial Cancer",
        "Sarcoma",
        "Squamous Cell Carcinoma of the Head and Neck",
        "Bladder Cancer",
        "Metastatic Castration Resistant Prostate Cancer",
        "Non-hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "CPI-006",
          "type": "DRUG"
        },
        {
          "name": "CPI-006 + ciforadenant",
          "type": "DRUG"
        },
        {
          "name": "CPI-006 + pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Corvus Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 117,
      "start_date": "2018-04-25",
      "completion_date": "2023-02-19",
      "has_results": false,
      "last_update_posted_date": "2023-12-21",
      "last_synced_at": "2026-05-21T23:28:42.636Z",
      "location_count": 22,
      "location_summary": "Tucson, Arizona • Duarte, California • San Francisco, California + 18 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03454451"
    },
    {
      "nct_id": "NCT04666129",
      "title": "Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Castration-Resistant Prostate Cancer",
        "Metastatic Castration-Sensitive Prostate Cancer",
        "Non-Metastatic Castration-Resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Relugolix",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "Apalutamide",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sumitomo Pharma America, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 48,
      "start_date": "2021-02-18",
      "completion_date": "2024-05-28",
      "has_results": false,
      "last_update_posted_date": "2025-08-17",
      "last_synced_at": "2026-05-21T23:28:42.636Z",
      "location_count": 16,
      "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Lakewood, Colorado + 13 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Lakewood",
          "state": "Colorado"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Worcester",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04666129"
    },
    {
      "nct_id": "NCT01695044",
      "title": "A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "PSMA ADC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Progenics Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 119,
      "start_date": "2012-09",
      "completion_date": "2015-02",
      "has_results": true,
      "last_update_posted_date": "2017-03-24",
      "last_synced_at": "2026-05-21T23:28:42.636Z",
      "location_count": 36,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Burbank, California + 32 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01695044"
    },
    {
      "nct_id": "NCT02215161",
      "title": "Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Castration Levels of Testosterone",
        "Hormone-Resistant Prostate Cancer",
        "Metastatic Prostate Carcinoma in the Soft Tissue",
        "Prostate Carcinoma Metastatic in the Bone",
        "PSA Progression",
        "Stage IV Prostate Adenocarcinoma AJCC v7"
      ],
      "interventions": [
        {
          "name": "Selinexor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 14,
      "start_date": "2014-09-02",
      "completion_date": "2018-04-02",
      "has_results": true,
      "last_update_posted_date": "2018-06-26",
      "last_synced_at": "2026-05-21T23:28:42.636Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02215161"
    },
    {
      "nct_id": "NCT06990880",
      "title": "A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Neoplasms, Prostate"
      ],
      "interventions": [
        {
          "name": "GSK5458514",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 85,
      "start_date": "2025-06-12",
      "completion_date": "2028-08-09",
      "has_results": false,
      "last_update_posted_date": "2026-04-24",
      "last_synced_at": "2026-05-21T23:28:42.636Z",
      "location_count": 2,
      "location_summary": "Denver, Colorado • Nashville, Tennessee",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06990880"
    },
    {
      "nct_id": "NCT03395197",
      "title": "Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "mCRPC"
      ],
      "interventions": [
        {
          "name": "Talazoparib with enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "Placebo with enzalutamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 1054,
      "start_date": "2017-12-18",
      "completion_date": "2027-06-30",
      "has_results": true,
      "last_update_posted_date": "2026-04-22",
      "last_synced_at": "2026-05-21T23:28:42.636Z",
      "location_count": 131,
      "location_summary": "Anchorage, Alaska • Chandler, Arizona • Gilbert, Arizona + 93 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03395197"
    },
    {
      "nct_id": "NCT01385293",
      "title": "BKM120 in Metastatic Castration-resistant Prostate Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer",
        "Metastatic (Spread to Other Areas of the Body)"
      ],
      "interventions": [
        {
          "name": "BKM120",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Andrew J. Armstrong, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 30,
      "start_date": "2011-08",
      "completion_date": "2016-02",
      "has_results": true,
      "last_update_posted_date": "2017-05-19",
      "last_synced_at": "2026-05-21T23:28:42.636Z",
      "location_count": 3,
      "location_summary": "Durham, North Carolina • Portland, Oregon • Seattle, Washington",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01385293"
    }
  ]
}